Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flupentixol + haloperidol + perazine
- Development stage
- Unknown
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination of three antipsychotic medications. Flupentixol and haloperidol are high-potency first-generation antipsychotics, while perazine is also an antipsychotic. This combination may be used in the treatment of schizophrenia and other psychotic disorders, particularly in cases where monotherapy is insufficient.
- Other names
- flupenthixol + haloperidol + perazine
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on flupentixol + haloperidol + perazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flupentixol + haloperidol + perazine.